Structural and Physicochemical Features of Oral PROTACs.

Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
30 Jul 2024
Historique:
medline: 30 7 2024
pubmed: 30 7 2024
entrez: 30 7 2024
Statut: aheadofprint

Résumé

Achieving oral bioavailability with Proteolysis Targeting Chimeras (PROTACs) is a key challenge. Here, we report the

Identifiants

DOI: 10.1021/acs.jmedchem.4c01017 PMID: 39078401
pubmed: 39078401
doi: 10.1021/acs.jmedchem.4c01017
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Markus Schade (M)

Chemistry and DMPK, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom.
ORCID: 0000-0002-5538-5767

James S Scott (JS)

Chemistry and DMPK, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom.
ORCID: 0000-0002-2263-7024

Thomas G Hayhow (TG)

Chemistry and DMPK, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom.
ORCID: 0000-0002-8555-375X

Andy Pike (A)

Chemistry and DMPK, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom.
ORCID: 0000-0001-6078-7501

Ina Terstiege (I)

Chemistry and DMPK, Research and Early Development, Respiratory and Immunology, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal 43183, Sweden.
ORCID: 0000-0003-4087-9710

Marie Ahlqvist (M)

Chemistry and DMPK, Research and Early Development, Respiratory and Immunology, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal 43183, Sweden.
ORCID: 0000-0002-1246-4350

Johan R Johansson (JR)

Chemistry and DMPK, Research and Early Development, Respiratory and Immunology, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal 43183, Sweden.
ORCID: 0000-0002-5764-4881

Coura R Diene (CR)

Chemistry and DMPK, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom.
ORCID: 0000-0002-6536-3940

Charlene Fallan (C)

Chemistry and DMPK, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom.
ORCID: 0000-0002-5964-1465

Amber Y S Balazs (AYS)

Chemistry, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States.
ORCID: 0000-0002-5556-6795

Elisabetta Chiarparin (E)

Chemistry and DMPK, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom.
ORCID: 0000-0002-2998-1346

David Wilson (D)

Chemistry and DMPK, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom.

Classifications MeSH